Partnerships University of Miami (exclusive worldwide license for Aging-related Frailty MSC technology)
Indications
hypoplastic left heart syndrome (HLHS)(Phase 2)
Alzheimer's disease(Phase 2)
pediatric dilated cardiomyopathy (DCM)(Stage not disclosed)
Aging-related Frailty(Stage not disclosed)
Catalysts
— not dated
Status note Lead and only investigational product candidate. ELPIS II: multicenter randomized double-blind controlled Phase 2b trial of laromestrocel as adjunct to second-stage HLHS heart reconstructive surgery (next step after completed 10-patient open-label Phase 1 ELPIS I). A second financing closing is contingent on ELPIS II Phase 2b results demonstrating statistical significance of agreed primary endpoints. AD: following March 2025 Type B FDA meeting, company seeks partnership/non-dilutive funding for proposed single seamless adaptive Phase 2/3. Pediatric DCM and Aging-related Frailty: in clinical development per filing, phases not stated in excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.